Navigation Links
Amylin Sends Letter to Shareholders
Date:5/1/2009

INNISFREE M&A INCORPORATED

Stockholders Call Toll-Free: (877) 717-3926

Banks and Brokers Call Collect: (212) 750-5833

IMPORTANT

We urge you NOT to vote using any White or Gold proxy card sent to you by Icahn or Eastbourne, as doing so will revoke your vote on the BLUE proxy card.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

Forward Looking Statements

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or exenatide once weekly may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansio
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Lilly and Amylin Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Cell Disruptor including its ... explores global and China’s top manufacturers of Cell ... and market share etc. The report further analyzes ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Grand Rapids, MI (PRWEB) August 30, 2014 ... Michigan residents, Forefront Dermatology is expanding with the addition ... Mich. Dr. David Hammond who has provided leading-edge skin ... practice with Forefront Dermatology. , “As a doctor, ... care they deserve. Through partnering with Forefront Dermatology, I’m ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:8/30/2014)... 30, 2014 "My wife suffered neck, ... car accident," said one of two inventors from Bethel, ... her shoulder and neck area. She tried other pillows ... and pressure, assisting in comfort and providing extra sleep." ... CRADLE to support the head, neck and back comfortably. ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... regimen in most cancer treatments. Since it is a very ... with something more comfortable for the patient. ,Now ... off the ovary and stop the production of a female ... agonist achieves a normal action, often mimicking the action of ...
... that intake of cruciferous vegetables with a high ... against bladder cancer. ... such as broccoli, cauliflower, kale, turnips, collards, Brussels ... ,They apply their anti-oxidant effect through down regulation ...
... only affects to work, sleep and performance of other activities ... memory and your concentration. ,This is the ... Saifudin Rashiq at the University of Alberta. ,As ... Multidisciplinary Pain Centre in Edmonton, Canada, the researchers studied 24 ...
... Researchers based at the National Cancer Institute and ... an antioxidant predominately found in tomatoes , does ... fact, the researchers noted an association between beta-carotene, ... risk for aggressive prostate cancer. ,It ...
... of a type of kidney malignancy called renal cancer according ... and Women's Hospital in Boston found that women and men ... were about 30 percent less likely to develop renal cell ... who drank beer, wine or liquor. ,Jung Eun ...
... the Australian National Audit Office found that the Department ... 100,000 people with tuberculosis to enter Australia but frequently ... treatment, The Australian reports. ,People with inactive ... sometimes are permitted to enter Australia if they sign ...
Cached Medicine News:Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Risk of Bladder Cancer Reduced by Broccoli and Cauliflower 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:Tomatoes are Not So Effective in Preventing Prostate Cancer 2
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... their offering. The Central Nervous System (CNS) ... of pharmaceuticals industry. The numbers of CNS disorders have increased ... to meet the market requirements. There has been steady to ... the past two decades. The market for CNS therapies is ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: